Advertisement

Tumor Biology

, Volume 37, Issue 3, pp 2961–2971 | Cite as

Roles of coinhibitory molecules B7-H3 and B7-H4 in esophageal squamous cell carcinoma

  • Ling Wang
  • Na-na Cao
  • Shan Wang
  • Hong-wei Man
  • Peng-fei Li
  • Bao-en Shan
Original Article

Abstract

The coinhibitory molecules, B7-H3 and B7-H4, have shown negative regulation in T cell activation and tumor-associated macrophage (TAM) polarization in tumor-specific immunity. Here, we investigated the expression of B7-H3 and B7-H4 in human and murine esophageal squamous cell carcinoma (ESCC) tissues to define their clinical significance and mechanism in a tumor microenvironment. In the present study, B7-H3 and B7-H4 were expressed in 90.6 and 92.7 % samples, respectively. High B7-H3 and B7-H4 expression was associated with advanced TNM stage and lymph node metastasis (p < 0.05, respectively). Patients with both B7-H3 and B7-H4 high-expressed tumors had the poorest prognosis (26.7 months), whereas those with both low-expressed tumors had the best survival (56.7 months). B7-H3 and B7-H4 expression were inclined to be positively related to the infiltration intensity of Treg cells and TAMs (p < 0.05, respectively), and B7-H3 expression is negatively associated with the intensity of CD8+ T cells (p < 0.05). In 4-nitroquinoline 1-oxide (4-NQO)-induced murine models, high B7-H3 expression could only be detected at carcinoma stage, but abnormal B7-H4 expression appeared a little earlier at dysplasia stage. In vitro studies revealed that knockdown of B7-H3 on tumor cells suppressed ESCC cell migration and invasion, while knockdown of B7-H4 could inhibit ESCC cell growth. Overall, B7-H3 and B7-H4 are involved in ESCC progression and development and their coexpression could be valuable prognostic indicators. Interference of these negative regulatory molecules might be a new strategy for treating ESCC.

Keywords

Coinhibitory molecules Esophageal squamous cell carcinoma B7-H3 B7-H4 

Notes

Acknowledgments

This program was financially supported by the National Natural Science Foundation of China (81173611, 81402228), HeBei Major Medical Scientific Research Foundation (Zd2013045), Hebei Natural Science Foundation (H2015206216), HeBei Province Medical Foundation (ZL20140334), and HeBei Province Education Foundation (QN2014049).

Conflicts of interest

None

Supplementary material

13277_2015_4132_MOESM1_ESM.pdf (221 kb)
Supplementary figure The detection of B7-H3 (A) and B7-H4 (B) gene expression in Eca-109 cells after siRNA interference via Real-time PCR and western blotting, respectively. GAPDH was used as an internal control. (PDF 221 kb)

References

  1. 1.
    Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400–12.CrossRefPubMedGoogle Scholar
  2. 2.
    Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol WJG. 2013;19:5598–606.CrossRefPubMedGoogle Scholar
  3. 3.
    Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, et al. Epidemiology of esophageal cancer in japan and china. J Epidemiol / Japan Epidemiol Assoc. 2013;23:233–42.CrossRefGoogle Scholar
  4. 4.
    Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, He J: Report of incidence and mortality in china cancer registries, 2009. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2013;25:10–21.Google Scholar
  5. 5.
    Esophageal cancer: Epidemiology, pathogenesis and prevention. Nature clinical practice Gastroenterology & hepatology 2008;5:517–526.Google Scholar
  6. 6.
    Napier KJ, Scheerer M, Misra S. Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointestinal Oncol. 2014;6:112–20.CrossRefGoogle Scholar
  7. 7.
    Wang L, Kang FB, Shan BE. B7-h3-mediated tumor immunology: friend or foe? Int J Cancer J Int Cancer. 2014;134:2764–71.CrossRefGoogle Scholar
  8. 8.
    Yu N, Li X, Zheng S, Li X. B7-H4’s role “beyond the tumor”. Inflammation. 2013;36:941–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Sun M, Richards S, Prasad DV, Mai XM, Rudensky A, Dong C. Characterization of mouse and human B7-H3 genes. J Immunol. 2002;168:6294–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4:899–906.CrossRefPubMedGoogle Scholar
  11. 11.
    Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A. 2007;104:19458–63.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wang L, Zhang Q, Chen W, Shan B, Ding Y, Zhang G, et al. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PLoS ONE. 2013;8, e70689.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kang FB, Wang L, Jia HC, Li D, Li HJ, Zhang YG, et al. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. 2015;15:45.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kang FB, Wang L, Li D, Zhang YG, Sun DX. Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7-H3 expression. Oncol Rep. 2015;33:274–82.PubMedGoogle Scholar
  15. 15.
    Prasad DV, Richards S, Mai XM, Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity. 2003;18:863–73.CrossRefPubMedGoogle Scholar
  16. 16.
    Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R, et al. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res. 2005;306:128–41.CrossRefPubMedGoogle Scholar
  17. 17.
    Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003;18:849–61.CrossRefPubMedGoogle Scholar
  18. 18.
    Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007;67:8900–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Chen LJ, Sun J, Wu HY, Zhou SM, Tan Y, Tan M, et al. B7-H4 expression associates with cancer progression and predicts patient’s survival in human esophageal squamous cell carcinoma. Cancer Immunol, Immunotherapy CII. 2011;60:1047–55.CrossRefGoogle Scholar
  20. 20.
    Wang L, Kang F, Li J, Zhang J, Shan B. Overexpression of p65 attenuates celecoxib-induced cell death in MDA-MB-231 human breast cancer cell line. Cancer Cell Int. 2013;13:14.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Quandt D, Fiedler E, Boettcher D, Marsch W, Seliger B. B7-H4 expression in human melanoma: its association with patients’ survival and antitumor immune response. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:3100–11.CrossRefGoogle Scholar
  22. 22.
    Wang J, Jia Y, Wang N, Zhang X, Tan B, Zhang G, et al. The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma. J Transl Med. 2014;12:7.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014;27:1–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Whiteside TL. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol, Immunotherapy CII. 2014;63:67–72.CrossRefPubMedGoogle Scholar
  25. 25.
    Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol. 2015;36:229–39.CrossRefPubMedGoogle Scholar
  26. 26.
    Laoui D, Van Overmeire E, De Baetselier P, Van Ginderachter JA, Raes G. Functional relationship between tumor-associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression. Front Immunol. 2014;5:489.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010;362:875–85.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Tseng SH, Yang CC, Yu EH, Chang C, Lee YS, Liu CJ, et al. K14-EGFP-miR-31 transgenic mice have high susceptibility to chemical-induced squamous cell tumorigenesis that is associating with Ku80 repression. Int J Cancer J Int Cancer. 2015;136:1263–75.CrossRefGoogle Scholar
  30. 30.
    Wilkey JF, Buchberger G, Saucier K, Patel SM, Eisenberg E, Nakagawa H, et al. Cyclin D1 overexpression increases susceptibility to 4-nitroquinoline-1-oxide-induced dysplasia and neoplasia in murine squamous oral epithelium. Mol Carcinog. 2009;48:853–61.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M, et al. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget. 2015;6:3452–61.CrossRefPubMedGoogle Scholar
  32. 32.
    Li M, Zhang G, Zhang X, Lv G, Wei X, Yuan H, et al. Overexpression of B7-H3 in CD14+ monocytes is associated with renal cell carcinoma progression. Med Oncol. 2014;31:349.CrossRefPubMedGoogle Scholar
  33. 33.
    Ingebrigtsen VA, Boye K, Nesland JM, Nesbakken A, Flatmark K, Fodstad O. B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome. BMC Cancer. 2014;14:602.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hu Y, Lv X, Wu Y, Xu J, Wang L, Chen W, et al. Expression of costimulatory molecule B7-H3 and its prognostic implications in human acute leukemia. Hematology. 2015;20:187–95.CrossRefPubMedGoogle Scholar
  35. 35.
    Lin DC, Du XL, Wang MR. Protein alterations in ESCC and clinical implications: a review. Diseases Esophagus Off J Int Soc Diseases Esophagus / ISDE. 2009;22:9–20.CrossRefGoogle Scholar
  36. 36.
    Sakai NS, Samia-Aly E, Barbera M, Fitzgerald RC. A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Semin Cancer Biol. 2013;23:512–21.CrossRefPubMedGoogle Scholar
  37. 37.
    Wang G, Sun Y, Ji C, He Y, Hu C, Jiang F, et al. Correlation between the CD4 + CD25high regulatory T cells and the outcome of chemotherapy in advanced esophageal carcinoma. Hepato-Gastroenterology. 2013;60:704–8.PubMedGoogle Scholar
  38. 38.
    Nabeki B, Ishigami S, Uchikado Y, Sasaki K, Kita Y, Okumura H, et al. Interleukin-32 expression and Treg infiltration in esophageal squamous cell carcinoma. Anticancer Res. 2015;35:2941–7.PubMedGoogle Scholar
  39. 39.
    Kristensen NN, Schmidt EG, Rasmussen S, Balk-Moller E, Claesson MH. B7-H4-Ig treatment of normal mice changes lymphocyte homeostasis and increases the potential of regulatory T cells. Immunopharmacol Immunotoxicol. 2013;35:505–13.CrossRefPubMedGoogle Scholar
  40. 40.
    Josephs DH, Bax HJ, Karagiannis SN. Tumour-associated macrophage polarisation and re-education with immunotherapy. Front Biosci. 2015;7:293–308.CrossRefGoogle Scholar
  41. 41.
    Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014;6:1670–90.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Medrek C, Ponten F, Jirstrom K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012;12:306.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Peng HX, Wu WQ, Yang DM, Jing R, Li J, Zhou FL, et al. Role of B7-H4 siRNA in proliferation, migration, and invasion of LOVO colorectal carcinoma cell line. BioMed Res Int. 2015;2015:326981.PubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Ling Wang
    • 1
  • Na-na Cao
    • 2
  • Shan Wang
    • 2
  • Hong-wei Man
    • 1
  • Peng-fei Li
    • 1
  • Bao-en Shan
    • 1
  1. 1.Cancer Research InstituteThe Fourth Hospital of Hebei Medical UniversityShijiazhuangChina
  2. 2.Blood Transfusion DepartmentThe Fourth Hospital of Hebei Medical UniversityShijiazhuangChina

Personalised recommendations